Beta-adrenoblockers of third generation as medicines for drug therapy of patients with chronic kidney disease

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review discusses the results of preclinical and clinical trials on the identification of nephroprotective action of β-blockers 3 generation carvedilol and nebivolol on models of hypertensive and diabetic nephropathy and patients with chronic kidney disease. It was concluded that nebivolol and especially carvedilol differs from its predecessors additional antioxidant and nephroprotective properties may be the drugs of choice from β-blockers for drug therapy of hypertensive patients with chronic kidney disease.

Full Text

Restricted Access

About the authors

Oleg B Kuzmin

Orenburg State Medical University

Author for correspondence.
Email: kuzmin.orgma@mail.ru
Head of the Department of Pharmacology

Vladislav V Zhezha

Orenburg State Medical University

Email: zhezha56@mail.ru
assistant professor of the Department of Pharmacology

Vitaly V Belyanin

Orenburg State Medical University

Email: Vitbelya@yandex.ru
assistant professor of the Department of Pharmacology

Natalya V Buchneva

Orenburg State Medical University

Email: buzap01@yandex.ru
assistant professor of the Department of Pharmacology

References

  1. Бучнева Н.В., Кузьмин О.Б. Влияние бета-адреноблокаторов третьего поколения на ионорегулирующую функцию почек крыс с моделью сердечной недостаточности // Экспер. и клин. фармакол. - 2012. - Т. 75. - № 11. - С. 7-9. [Buchneva NV, Kuz’min OB. Vliyanie beta-adrenoblokatorov tret’ego pokoleniya na ionoreguliruyushhuyu functsiyu pochek krya s model’yu serdechnoj nedostatochnosti. Eksperimental’naya i klinicheskaya farmakologia. 2012;75(11):7-9. (In Russ).]
  2. Кузьмин О.Б., Пугаева М.О., Жежа В.В. Нефропротективная терапия гипертензивных больных с хронической болезнью почек: есть ли в ней место для бета-адреноблокаторов третьего поколения и агонистов I1-имидазолиновых рецепторов? // Нефрология. - 2006. - Т. 10. - № 2. - С. 18-27. [Kuz’min OB, Pugaeva MO, Zhezha VV. Nefroprotektivnaya terapiya gipertensivnykh bol’nykh s khronicheskoj bolesn’yu pochek: est’ li v nej mesto dlya beta-adrenoblokatorov trt’ego pokoleniya i agonistov I1-imidazolinovykh retseptorov? Nefrologia. 2006;10(2):18-27. (In Russ).]
  3. Кузьмин О.Б., Белянин В.В., Жежа В.В. Нефропротекторные свойства бета-адреноблокаторов третьего поколения // Экспер. и клин. фармакол. - 2014. - Т. 77. - № 3. - С. 40-43. [Kuz’min OB, Belyanin VV, Zhezha VV. Nefroprotektornye svojstva beta-adrenoblokatorov trt’ego pokoleniya. Eksperimental’naya i klinicheskaya farmakologia. 2014;77(3):40-43. (In Russ).]
  4. Смирнов А.В., Добронравов В.А., Кисина А.А., и др. Клинические рекомендации по диагностике и лечению диабетической нефропатии // Нефрология. - 2015. - Т. 19. - № 1. - С. 67-77. [Smirnov AV, Dobronravov VA, Kisina AA, et al. Klinicheskie rekomendatsii po diagnostike i lecheniyu diabeticheskoj nefropatii. Nefrologia. 2015;19(1):67-77. (In Russ).]
  5. Abdel-Raheem MH, Salim SU, Mosad E, et al. Antiapoptic and antioxidant effects o carvedilol and vitamin E protects against diabetic nephropathy and cardiomyopathy in diabetic Wistar albino rats. Horm Metab Res. 2015;47(2):97-106. doi: 10.1055/s-0034-1385855.
  6. Arab HH, El-Sawalhi MM. Carvedilol alleviates adjuvant-induced arthritis and subcutaneous air pouch edema: modulation of oxidative stress and inflammatory mediators. Toxicol Appl Pharmacol. 2013;268(2):241-248. doi: 10.1016/j.taap.2013.01.013.
  7. Barone FC, Nelson AH, Ohlstein EH, et al. Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther. 1996;279(2):948-955.
  8. Bakris GL, Fonseca V, Katholi RE, et al. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. Hypertension. 2005;46(6):1309-1315. doi: 10.1161/01.HYP.0000190585.54734.
  9. Bakris GL, Hart P, Ritz E. Beta-blockers in the management of chronic kidney disease. Kidney Int. 2006;70(11):1905-1911. doi: 10.1038/sj.ki.5001835.
  10. Brooks DP, Short BJ, Cyronak MJ, et al. Comparison between carvedilol and captopril in rats with partial oblation-induced chronic renal failure. Br J Pharmacol. 1993;109(2):581-586. doi: 10.1111/j.1476-5381.1993.tb13610.x.
  11. Ceron CS, Rizzi E, Guimaraes DA, et al. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension. Free Radic Biol Med. 2013;65:47-56. doi: 10.1016/j.freeraddiomed/2013.06.033.
  12. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from SENIORS trial. Eur J Heart Fail. 2009;11(9):872-880. doi: 10.1093/eurjhf/hfp104.
  13. Duranay M, Kanbay M, Akay H, et al. Nebivolol improves renal function in patients who underwent angioplasty due to renal artery stenosis: a pilot study. Nephron Clin Pract. 2010;114 (3):213-217. doi: 10.1159/000262304.
  14. Fassbinder W, Quarder O, Waltz A. Treatment with carvedilol is associated with a significant reduction of microalbuminuria: a multicentre randomized study. Int J Clin Practic. 1999;53(7):519-522.
  15. Gao G, Llambi HG, Ottaviano G, et al. Carvedilol protects the peritubular capillaries and kidney structure in spontaneously hypertensive rats. Int J Cardiol. 2015;81:415-416. doi: 10.1016/j.ijcard.2014.12/049.
  16. Gomes A, Costa D, Lima JL, Fernandes E. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species. Bioorg Med Chem. 2006;14 (13):4568-4577. doi: 10.1016/j.bmc.2006.02.023.
  17. Greeven J, Gabriels G. Effect of nebivolol, a novel β1-selective adrenoceptor antagonist with vasodilating properties, on kidney function. Arzneimittel-Forschung. 2000;50(11):973-979.
  18. Hart PD, Bakris GL. Should beta-blockers be used to control hypertension in people with chronic kidney disease. Semin Nephrol. 2007;27(5):555-564. doi: 10.1016/j.semnephrol.2007.07.003.
  19. Hayden MR, Habibi J, Whaley-Connell A, et al. Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. Am J Nephrol. 2010; 31(3):262-272. doi: 10.1159/000278757.
  20. KDIGO Blood Pressure Work Group. KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease. Chapter 2. Lifestyle and pharmacological treatments for lowering blood pressure in CKD ND patients. Kidney Int Suppl. 2012;2(5):347-356. doi: 10.1038/kisup.2012.52.
  21. Khan MU, Zhao W, Zhao T, et al. Nebivolol: a multifacetered antioxidant and cardioprotectant in hypertensive heart disease. J Cardiovasc Pharmacol. 2013;82(5):445-451. doi: 10.1097/FCJ.0b013e318a0b5ff.
  22. Lysko PG, Webb CL, Gu JC, et al. A comparison of carvedilol and metoprolol antioxidant activities in vitro. J Cardiovasc Pharmacol. 2000;36(2):277-281. doi: 10.1097/00005344-200008000-00020.
  23. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicentre randomized, open-label, controlled study versus atenolol. Adv Ther. 1995;12(4):212-221.
  24. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009;3(4):317-327. doi: 10.1177/1753944709104496.
  25. Moningka MC, Tsarova T, Sasser JM, Baylis C. Protective actions of nebivolol on chronic nitric oxide synthase inhibition-induced hypertension and chronic kidney disease in the rat: a comparison with angiotensin II receptor blockade. Nephrol Dial Transplant. 2012;27(3):913-920. doi: 10.1093/ndt/gfr449.
  26. Mory MA, Ibrahim SA, Amin EF, et al. Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int. 2014;2014:105214. doi: 10.1155/2014/105214.
  27. Neumann J, Ligtenberg G, Klein IH, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension. 2007;49(3):506-510. doi: 10.1161/01/HYP.0000256530.39695.a3.
  28. Rodriges MA, Gobe G, Santos NA, Santos AC. Carvedilol protects against apoptic cell death induced by cisplatin in renal tubular epithelial cells. J Toxicol Environ Health. 2012;75(16-17):981-990. doi: 10.1080/15287394.2012.696512.
  29. Sasser JM, Moningka MC, Tsarova T, Baylis C. Nebivolol does not protect against 5/6 oblation/infarction induced chronic kidney disease in rats - comparison with angiotensin II receptor blockade. Life Sci. 2012;91(1-2):54-63. doi: 10.1016/j.lfs.2012.06.005.
  30. Toblli JE, Cao G, Giani JF, et al. Long-term treatment with nebivolol attenuates renal damage in Zucker diabetic fatty rats. J Hypertens. 2011;29(8):1613-1623. doi: 10.1097/HJH.0b013e328349064c.
  31. Varagic J, Ahmad S, Brosnihan KB, et al. Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol. 2010;32(6):557-566. doi: 10.1159/000321471.
  32. Verbeke F, Lindley E, van Bortel L, et al. European Renal Best Practice (ERBP) position. Statement on the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines for the management of blood pressure in non-dialysis-dependent chronic kidney disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant. 2014;29(3):490-496. doi: 10.1093/ndt/gft321.
  33. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol treatment of heart failure in chronic kidney disease: a meta-analysis of randomized trials. Circ Heart Fail. 2011;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558.
  34. Walker LM, Walker PD, Imam SZ, et al. Evidence for peroxynitrite formation in renal ischemia-reperfusion injury: studies with the inducible nitric oxide synthase inhibitor LN(6)-(1-Iminoethyl)lysine. J Pharmacol Exp Ther. 2000;295(1):417-422.
  35. Whaley-Connell A, Habibi J, Johnson M, et al. Nebivolol reduced proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren 2 rats. Am J Nephrol. 2009;30(4):354-360. doi: 10.1159/000229305.
  36. Wong VY, Laping NG, Nelson AH, et al. Renoprotective effects of carvedilol in hypertensive stroke-prone rats may involve inhibition of TGF-beta expression. Br J Pharmacol. 2001;134 (5):977-984. doi: 10.1038/sj.bjp.0704329.

Copyright (c) 2016 Kuzmin O.B., Zhezha V.V., Belyanin V.V., Buchneva N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 65565 от 04.05.2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies